Basem William, MD
Hematology & Oncology · Marion, OHNPI 1952416505
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.7%. 2025 is the largest year on record at $10,014, 2.4 times the $4,232 reported in 2019.
Across 106 payments — averaging $339.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$8K
- E.r. Squibb & Sons, L.L.C.$4K
- AstraZeneca$3K
- Karyopharm Therapeutics Inc.$3K
- Genmab U.S., Inc.$3K
- Bristol Myers Squibb$3K
- plus $13K from 21 others
Across 131 payments — averaging $5429.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$291K
- AbbVie$141K
- Otsuka Pharmaceutical Co., Ltd.$138K
- Karyopharm Therapeutics Inc.$46K
- Beone Medicines Ltd.$34K
- ADC Therapeutics America, Inc.$21K
- plus $41K from 7 others
What the payments were for
- Consulting fees$17,69449%
- Speaking & faculty fees$8,60824%
- Travel & lodging$4,81513%
- Food & beverage$4,74213%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 7 | $7,794 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,806 |
| AstraZeneca(2 entities) | 5 | $3,069 |
| Karyopharm Therapeutics Inc. | 15 | $3,030 |
| Genmab U.S., Inc. | 11 | $2,908 |
| Bristol Myers Squibb | 5 | $2,798 |
| Incyte Corporation | 4 | $2,686 |
| ADC Therapeutics America, Inc. | 1 | $2,400 |
| Adaptive Biotechnologies Corporation | 20 | $2,247 |
| Morphosys, US Inc. | 2 | $1,935 |
| Pfizer | 2 | $1,124 |
| Gilead | 7 | $569 |
| National Marrow Donor Program | 2 | $317 |
| Novartis | 3 | $282 |
| Seagen Inc. | 2 | $204 |
| Syndax Pharmaceuticals, Inc. | 2 | $148 |
| AbbVie | 1 | $124 |
| Sanofi-aventis U.S. LLC | 1 | $120 |
| Dova Pharmaceuticals | 1 | $95 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Amgen | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $48 |
| Daiichi Sankyo Inc. | 1 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $18 |
| CTI Biopharma Corp. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,946 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 14 | $605,005 |
| BrukinsaZanubrutinib | 30 | $419,058 |
| ImbruvicaIbrutinib | 13 | $329,242 |
| InqoviDecitabine/Cedazuridine | 11 | $95,402 |
| Bexarotene | 15 | $18,262 |
| Entecavir | 17 | $6,731 |
| Levothyroxine Sodium | 27 | $547 |
| Acyclovir | 42 | $428 |
| Prochlorperazine Maleate | 15 | $113 |
| Oxycodone Hcl | 11 | $94 |
| Gabapentin | 11 | $61 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 14 | $54 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $48 |
| Prednisone | 20 | $44 |
| Allopurinol | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Marion
- Yanis BoumberMarion$101K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.